Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 28, 2014; 20(24): 7849-7863
Published online Jun 28, 2014. doi: 10.3748/wjg.v20.i24.7849
Table 2 Ongoing biomarker directed therapy trials in pancreatic carcinoma
Trial identifier1Name of studyPhaseSponsorArmsPrimary outcomeBiomarker
ACTRN12612000777897The IMPACT trial: Individualised Molecular Pancreatic Cancer Therapy A randomised open label phase II study of standard first line treatment or personalised treatment in patients with recurrent or metastatic pancreatic cancerIIThe Australasian Gastro-Intestinal Trials Group Collaborating groups:Australian Pancreatic Cancer Genome Initiative Sydney Catalyst; the Translational Cancer Research Centre of Central Sydney and Regional NSWPatients with actionable phenotypes randomised 1:1 to Standard -gemcitabine aloneORPersonalised Treatment -allocated based on molecular phenotype:HER2 positive sub-group - gemcitabine plus trastuzumab Homologous recombinant defects subgroup: 5FU plus MMCantiEGFR responsive sub-group: gemcitabine plus erlotinibProgression free survival (initial pilot phase will assess feasibility of personalised approach)Identification of actionable phenotypes based on molecular phenotype in tumour tissue in one of 3 subgroups:HER2 positive (HER2/neu amplification) subgroupHomologous recombination defects (BRCA1, BRCA2 or PALB2 mutation)AntiEGFR phenotype subgroup (KRAS wildtype or KRAS codon 13 mutation)
NCT01188109Gemcitabine/cisplatin for resected pancreas cancer: Establishing the role of ERCC1 in treatment decisionIIEmory UniversityGemcitabine and cisplatinProgression free survival and overall survivalImmunohistochemistry, rt-PCR, and single nucleotide polymorphism assessment to determine status of ERCC1 expression and gene
NCT01488552A Phase II study of induction consolidation and maintenance approach for patients with advanced pancreatic cancerI/IIPancreatic Cancer Research TeamGemcitabine + Nab-paclitaxel inductionFOLFIRINOX consolidative Metformin + targeted agent selected by biomarkers for maintenanceComplete response rateIHC Analysis will be performed on a fresh tissue biopsy of the tumor after chemotherapy has been administered. A targeted-based regimen will be determined from the results of the IHC analysis for the next therapy given to the patient in the maintenance phase of the study
NCT01524575Gemcitabine and oxaliplatin in the management of metastatic pancreatic cancers with low expression of ERCC1Phase IIUniversity of HawaiiGemcitabine+oxaliplatin6 mo overall survivalLow expression of ERCC1 protein and mRNA expression
NCT01888978A Pilot Study of Molecularly Tailored Therapy for Patients With Metastatic Pancreatic CancerPhase IIGeorgetown UniversityGemcitabine+oxaliplatinGemcitabine + 5FUGemcitabine + docetaxelFOLFOX6Oxaliplatin + docetaxelFOLFIRIDocetaxel-irinotecanTiming of biopsy and treatmentNumber of days from study entry to biopsy to molecular results to first doseSelection of doublet treatment on basis of molecular analysis of tumour
NCT01585805Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Patients With Locally Advanced or Metastatic Pancreatic CancerRandomised phase IINational Cancer InstituteCisplatin+gemcitabine+/-veliparibOptimal dose of veliparibResponse rateBRCA1 or BRCA2 mutation carrier
NCT01586611Study of Gemcitabine vs FOLFOX in the First Line Setting for Metastatic Pancreatic Cancer Patients Using Human Equilibrative Nucleoside Transporter 1 (hENT1) Biomarker TestingPhase IIIAHS Cancer Control AlbertaFOLFOXGemcitabinePFS between arms in hENT1 high and hENT1 low patientshENT1
NCT01454180Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic TargetsPhase IICentro Nacional de Investigaciones Oncologicas CARLOS IIIArm A: Physician discretionArm B: Therapeutic target guidedGemcitabineGemcitabine + capecitabineGemcitabine + erlotinibFOLFOXIRIFOLFOXFOLFIRIOverall survivalTherapeutic targets expressed in tumour tissue
NCT01726582Molecular Profiling to Guide Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the PancreasPhase IIMedical College of WisconsinTargeted chemotherapy prior to surgeryStandard FOLFIRINOX chemotherapy prior to surgeryGemcitabine after surgeryNo additional therapy after surgeryTargeted chemotherapy after surgeryChemoradiotherapyResectability rateMolecular profile of tumour will point to particular chemotherapy treatment
(Targeted chemotherapy include the following schedules: FOLFIRINOX, FOLFIRI, gemcitabine+irinotecan, gemcitabine + oxliplatin, gemcitabine + cisplatin, gemcitabine+nab-paclitaxel, capecitabine + nab-paclitaxel, gemcitabine, capecitabine, 5FU)